Overview of the Interim Report
Karolinska Development AB (Nasdaq Stockholm: KDEV) has published its detailed Interim Report for the period from January to June 2024. This report provides valuable insights into the company's activities and performance during the first half of the year.
Insights from the CEO and Portfolio Updates
Viktor Drvota, the CEO of Karolinska Development, shared his positive outlook on the company's recent accomplishments and future plans. "The successes we've highlighted from this quarter reflect the significant activities happening within our portfolio, and we anticipate an equally dynamic autumn," Drvota stated. He also pointed out that BOOST Pharma is expected to announce the final results from its clinical phase 1/2 study before the year concludes.
Quarterly Highlights
Several important events took place within the portfolio during the second quarter:
- Umecrine Cognition has commenced the second phase of its clinical phase 1b/2 study for golexanolone, having randomized its first two patients. Results are anticipated in the first half of 2025.
- During the Annual General Meeting, key decisions were made, including the approval of the profit and loss statements and the election of Hans Wigzell as Chairman of the Board.
- Karolinska Development made a strategic investment in BOOST Pharma, a company dedicated to developing innovative treatments for osteogenesis imperfecta, which is now part of its portfolio.
- Biosergen received final approvals to conduct tests on its candidate drug for treating invasive fungal infections in India.
Developments After the Reporting Period
Following the reporting period, several significant developments occurred:
- Umecrine Cognition successfully raised capital through a convertible loan to advance the development of golexanolone, with Karolinska Development participating alongside other investors.
- PharmNovo secured EUR 17.5 million in funding from the European Innovation Council (EIC), which will support the clinical development of its novel treatment for neuropathic pain.
Financial Summary
The financial results indicated a challenging quarter:
- The net loss for the second quarter was SEK -16.0 million, an improvement from SEK 23.3 million in the same period last year.
- The change in fair value for portfolio companies resulted in SEK -11.1 million, primarily due to fluctuations in share prices during recent investment rounds and other holdings.
- The total fair value of the portfolio reached SEK 1,454 million, showing a slight increase from the prior quarter.
- Net asset value decreased slightly to SEK 1,238.2 million, with cash and cash equivalents falling to SEK 49.7 million by the end of June.
About Karolinska Development
Karolinska Development AB is a prominent life sciences investment company that focuses on discovering innovative medical advancements. The company is committed to fostering the growth of businesses that aim to deliver significant medical breakthroughs to the market.
By partnering with world-class medical innovations and talented entrepreneurs, Karolinska Development strives to build a strong pipeline of treatments that can make a meaningful difference in patients' lives while providing attractive returns for investors.
Management Contacts
For more information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02
Email: viktor.drvota@karolinskadevelopment.com
Hans Christopher “HC” Toll, CFO, Karolinska Development AB
Phone: +46 70 717 00 41
Email: hc.toll@karolinskadevelopment.com
Frequently Asked Questions
What is the focus of Karolinska Development AB?
Karolinska Development AB invests in innovative medical advancements and develops companies that aim to bring groundbreaking treatments to market.
What were the financial results for the second quarter?
The company reported a net loss of SEK -16.0 million for the second quarter, compared to a profit in the prior year.
Who is the CEO of Karolinska Development?
Viktor Drvota serves as the CEO of Karolinska Development AB.
What investments have recently been made by Karolinska Development?
Karolinska Development has recently invested in BOOST Pharma and participated in the capital raise for Umecrine Cognition.
How does Karolinska Development ensure success in its investments?
The company collaborates with top scientists and experienced management teams, supported by specialist investors to increase the likelihood of success.